Allergan Breast Implant Lawsuit Lawsuit

“Allergan's own pharmacovigilance team documented BIA-ALCL cases associated with BIOCELL textured implants in internal vigilance reports beginning in 2011. These reports — produced during MDL 2921 discovery — establish that Allergan's medical affairs and regulatory departments were aware of the emerging lymphoma signal years before the FDA recall and years before any patient-facing labeling update was made. The 2011 reports identified a pattern: BIA-ALCL diagnoses clustering in women with BIOCELL textured implants. Allergan's failure to act on this internal knowledge — by updating physician communications, Dear Healthcare Provider letters, or patient labeling — forms the core of the failure-to-warn claim.”

“The FDA's MAUDE database contains over 1,130 unique BIA-ALCL cases as of 2024, with Allergan BIOCELL implants represented in a disproportionate share of confirmed cases. The database includes Medical Device Reports (MDRs) submitted by Allergan itself under its FDA post-market surveillance obligations — filed after the company received individual BIA-ALCL reports from physicians and hospitals. These Allergan-submitted MDRs are public records documenting that the company reported individual BIA-ALCL cases to the FDA while simultaneously declining to update patient or physician labeling. The MAUDE database also reflects reports from other manufacturers, enabling the comparative analysis that showed BIOCELL's elevated per-implant BIA-ALCL risk.”

“A series of landmark peer-reviewed publications using PROFILE registry data established BIA-ALCL's epidemiology, clinical presentation, and implant-surface associations. Key publications include: (1) Doren et al. (2017, Plastic and Reconstructive Surgery) — the first large registry-based analysis showing textured implants' disproportionate BIA-ALCL association; (2) Clemens et al. (2019, JAMA Oncology) — PROFILE registry analysis of 115 BIA-ALCL cases establishing treatment outcomes and survival data; and (3) multiple analyses confirming that BIOCELL implants carry the highest per-implant BIA-ALCL risk among commercially available textured devices. These publications were available to Allergan's medical and regulatory affairs teams and were cited in FDA advisory panel materials before the 2019 recall.”

“The FDA's July 24, 2019 press release announcing the Allergan BIOCELL recall is a primary document in all Allergan breast implant litigation. The recall letter sent to Allergan formally documents: (1) the FDA's determination that BIOCELL implants' benefit-risk profile was unacceptable based on the six-fold higher BIA-ALCL rate versus other textured implants; (2) that the FDA had recommended the recall and Allergan initially declined; (3) that the FDA invoked its mandatory recall authority under 21 U.S.C. § 360h(b); and (4) that Allergan agreed to a worldwide recall affecting all BIOCELL products. FDA Commissioner Sharpless's accompanying statement explicitly noted that 'Allergan declined to act voluntarily' before the FDA's mandatory authority was invoked. The recall letter's product specifications provide the definitive list of recalled BIOCELL devices for case qualification purposes.”

“Plaintiffs' expert witnesses in MDL 2921 have produced expert reports addressing: (1) the specific mechanism by which BIOCELL's salt-loss texturing produces a pathologically rough surface that sheds silicone particles and drives T-cell lymphomagenesis — authored by biomaterials and surface science experts; (2) general causation testimony by oncologists and immunologists establishing the causal pathway from BIOCELL texturing to BIA-ALCL; (3) specific causation opinions by treating oncologists and plastic surgeons in individual bellwether cases; and (4) regulatory experts documenting Allergan's failure to comply with FDA post-market surveillance obligations and update patient/physician labeling when the BIA-ALCL signal emerged. Allergan's Daubert motions challenging plaintiffs' general causation experts were substantially denied by Judge Martinotti, preserving the core causation framework for trial.”